Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.50 -0.15 (-0.34%)
Streaming Delayed Price Updated: 9:58 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 155,816
Open 44.64
Bid (Size) 44.48 (600)
Ask (Size) 44.53 (200)
Prev. Close 44.65
Today's Range 44.41 - 44.90
52wk Range 29.66 - 44.92
Shares Outstanding 388,132,400
Dividend Yield 1.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Mid-Cap Stocks We Keep Off Our Radar
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory

Performance

YTD
+14.5%
+14.5%
1 Month
+10.8%
+10.8%
3 Month
+15.5%
+15.5%
6 Month
+23.0%
+23.0%
1 Year
+40.3%
+40.3%

More News

Read More
News headline image
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
Why Is TEVA Stock Rising Pre-Market Today? ↗
Via Stocktwits
News headline image
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Overrated Stocks We Steer Clear Of
Via StockStory
News headline image
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks We’re Skeptical Of
Via StockStory
Topics Stocks
News headline image
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗
Via Chartmill
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Mid-Cap Stocks That Concern Us
Via StockStory
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Via Investor's Business Daily
News headline image
3 Value Stocks with Warning Signs
Via StockStory
Topics Supply Chain
News headline image
3 Low-Volatility Stocks We Find Risky
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
Via StockStory
Topics Stocks Supply Chain
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
Via Benzinga
Topics Economy

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 44.50
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 02/09/26 09:58 AM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 17.27B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 17B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.